Secondary Hypersplenism
Conditions
Brief summary
This study assesses the effectiveness of microwave ablation of the spleen in conjunction with splenic artery occlusion for treating secondary hypersplenism.
Detailed description
This open-label, single-arm, single-center clinical trial investigates the combined approach of microwave ablation of the spleen and splenic artery occlusion for managing secondary hypersplenism.
Interventions
PROCEDUREmicrowave ablation of the spleen
Ultrasound-guided percutaneous puncture for splenic ablation treatment
OTHERSplenic artery balloon implantation
Splenic artery balloon implantation
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 1\. written informed consent signed prior to enrolment 2. age \> 18 years, both sexes 3.Patients with severe hypersplenism secondary to cirrhosis with clinical diagnosis, White blood cells \<3×109/L, and/or platelet \<50×109/L 4.Patients who have been repeatedly given drugs to raise white blood cells and platelets in clinical practice have poor effect 5.Mental problems such as clinical symptoms or anxiety in patients require interventional treatment for hypersplenism
Exclusion criteria
* Patients with any of the following are not eligible for enrollment in this study 1. Coagulopathy or other blood disorders 2. Recent use of anticoagulant drugs 3. Severe hypertension and cardiac insufficiency 4. Bone marrow aspiration results showed bone marrow suppression 5. Combined with other spleen malignant diseases 6. Severe skin infection at the puncture site 7. Participated in other clinical studies within 2 months prior to the start of the study 8. Patient or his/her authorized person is unwilling to sign a written informed consent form or unwilling to comply with the study protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dynamic changes in platelet and white blood cell counts in routine blood tests | Up to 1 year | Platelet and WBC count changes on CBC |
| Hepatic artery blood flow velocity | Up to 1 year | Hepatic artery blood flow velocity |
| Routine blood test | Up to 1 year | Platelet count |
| Adverse Events | Up to 1 year | Adverse Events |
Countries
China
Contacts
CONTACTWEI LU, PhD
PRINCIPAL_INVESTIGATORWEI LU, PhD
Tianjin Cancer Hospital
Outcome results
None listed